~~<i id='BB100376F5'><strike id='BB100376F5'><tt id='BB100376F5'><pre id='BB100376F5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

comprehensive

author：fashion 2025-09-02 22:07:18 - browse：86992

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Attacks on the drug industry will lead to fewer breakthroughs

leisure time

focus

hotspot

knowledge

explore

AdobeWASHINGTON— Medicareofficialsaremovingforwardwithaplantoclawbackmoneyfromcertainhospitalstotryt

WSS

The drug industry sees a key ally in the Senate prevail

Humana, CVS hope to turn members into patients at clinics

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Biden calls for immediate release of Niger's president amid apparent coup

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Brain injuries and the importance of a second opinion

leisure time

comprehensive

Featured Speakers

leisure time

Drug repurposing or repositioning? The language matters

My superpower is killing ticks

State Dept. review finds Biden bears some blame for Afghanistan failures

'Ancient DNA,' 23andMe reveal African American ancestries

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Walensky prepares to leave CDC — and Congress — behind

White House drug shortage group privately met with industry

In age of alternative facts, a scholarly course on calling out crap

Medicare must police algorithms in Medicare Advantage, Dems say

focus

Stem cell clinics for heart failure: buyer be wary

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Live blog: Hearing on CRISPR

For BCIs, commercial hurdles may be bigger than scientific ones

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

hotspot

knowledge

explore

explore